Special Issue "Non-Alcoholic Fatty Liver Disease Research 2016"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 June 2016).
A printed edition of this Special Issue is available here.
Interests: NAFLD-MAFLD; cirrhosis; hepatocellular carcinoma; metabolic syndrome; insulin resistance; sex differences
Special Issues and Collections in MDPI journals
Special Issue in International Journal of Molecular Sciences: Metabolic Associated Fatty Liver Disease (MAFLD) Research 2020-2021
Topical Collection in Metabolites: Insulin Resistance in the 2020's
This Special Issue of IJMS, entitled “Non-Alcoholic Fatty Liver Disease Research 2015" will cover a selection of recent research topics and current review articles in the field of nonalcoholic fatty liver disease (NAFLD). NAFLD is the most common cause of chronic liver disease in Western countries and is predicted to be the most common cause of liver transplantation by 2030.
NAFLD has a bidirectional and inextricable association with metabolic disorders of which it is both the cause and the effect. On these grounds, it comes as no surprise that the clinical and social burden of NAFLD is not only confined to liver-related morbidity and mortality (e.g., cirrhosis, liver failure, and hepatocellular carcinoma), and that NAFLD is a truly a multisystem disease, affecting multiple regulatory pathways and pathophysiologically linked with several extra-hepatic diseases. For example, NAFLD increases the risk of developing type 2 diabetes, and cardiovascular and cardiac diseases. Moreover, NAFLD is also linked to other invalidating chronic conditions, such as hepatitis C virus (HCV), HIV infections, chronic kidney disease, extra-hepatic cancers, and chronic plaque psoriasis.
Against this background, further research is needed to understand genetic modifiers, natural history, and the molecular pathogenesis of NAFLD, as well as the biological mechanisms by which NAFLD influences the risk of hepatocarcinoma and extra-hepatic diseases. It is also important to establish whether there are key ‘common threads’ that link NAFLD to the development of extra-hepatic diseases.
Some of the leading researchers in this area have accepted to contribute to this Special Issue of IJMS in order to provide an updated, state-of-the-art view on these topics, as well as to indicate novel research avenues.
Dr. Amedeo Lonardo
Dr. Giovanni Targher
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- anticoagulation therapy
- arterial hypertension
- cardiovascular disease and risk
- clinical trials
- gut microbiota
- insulin resistance
- metabolic syndrome
- molecular biology
- natural history
- nonalcoholic fatty liver disease
- system biology
- type 2 diabetes
- thyroid disease
- uric acid